SOURCE: StockCall


June 25, 2012 08:15 ET

Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drug Companies Settling Lawsuits, Releasing New Products

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jun 25, 2012) - offers free research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI) from the Drugs - Generic industry. Access these reports by clicking on the links below or by copy and pasting those to your address bar.

As patents continue to expire and generic companies release alternatives to popular drugs, a plethora of lawsuits are also cropping up. Several generic companies have been able to successfully settle issues of late though, which is good news for the industry moving forward. is an online platform where investors doing their due-diligence on the Drugs - Generic industry can have easy and free access to our analyst research and opinions on Mylan Inc. and Watson Pharmaceuticals Inc. To see how companies in this industry have grown over the past years and how they are expected to perform in the future, please visit the link below.

One company with a number of recent courtroom wins is Watson Pharmaceuticals Inc. The company recently stated that the U.S. Court of Appeals for the Federal Circuit has established that claims relating to Sanctura XR® are invalid. Watson's Abbreviated New Drug Application for a generic version of the drug is pending with the FDA. Watson has also recently come to an agreement with Endo Pharmaceuticals regarding two patent infringement suits against Watson, in regards to Lidoderm. Register now to have free access to our report on Watson Pharmaceuticals Inc., and to do so please click the link below.

Across the pond, Mylan Inc. has stated that its subsidiaries in the U.K. and Italy have commenced selling Lamivudine Film coated Tablets, used in the treatment of HIV. The product is a generic of Epivir® Tablets, which are put out by GlaxoSmithKline. Investors and shareholders of Mylan Inc. can simply register for our complimentary reports by clicking on the link below.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information